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Abstract
Background: Classification systems may be useful to direct more aggressive treatment to cancer
patients with a relatively poor prognosis. The definition of 'poor prognosis' often lacks a formal
basis. We propose a decision analytic approach to weigh benefits and harms explicitly to define the
treatment threshold for more aggressive treatment. This approach is illustrated by a case study in
advanced testicular cancer, where patients with a high risk of mortality under standard treatment
may be eligible for high-dose chemotherapy with stem cell support, which is currently defined by
the IGCC classification.
Methods:  We used published literature to estimate the benefit and harm of high-dose
chemotherapy (HD-CT) versus standard-dose chemotherapy (SD-CT) for patients with advanced
non-seminomatous germ cell cancer. Benefit and harm were defined as the reduction and increase
in absolute risk of mortality due to HD-CT respectively. Harm included early and late treatment
related death, and treatment related morbidity (weighted by 'utility').
Results: We considered a conservative and an optimistic benefit of 30 and 40% risk reduction
respectively. We estimated the excess treatment related mortality at 2%. When treatment related
morbidity was taken into account, the harm of HD-CT increased to 5%. With a relative benefit of
30% and harm of 2 or 5%, HD-CT might be beneficial for patients with over 7 or 17% risk of cancer
specific mortality with SD chemotherapy, while with a relative benefit of 40% HD-CT was beneficial
over 5 and 12.5% risk respectively. Compared to the IGCC classification 14% of the patients would
receive more aggressive treatment, and 2% less intensive treatment.
Conclusion:  Benefit and harm can be used to define 'poor prognosis' explicitly for non-
seminomatous germ cell cancer patients who are considered for high-dose chemotherapy. This
approach can readily be adapted to new results and extended to other cancers to define candidates
for more aggressive treatments.
Background
The prognosis of a cancer patient is of key importance in
the choice of more or less aggressive treatment. Prognostic
estimates can be based on extent of disease, as for example
reflected in TNM stage, on age and comorbidity, and on
specific characteristics, such as values of tumour markers
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[1]. Prognostic classifications can facilitate decision-mak-
ing by grouping patients with a similar prognosis. Poor
prognosis patients may be considered candidates for more
aggressive treatment strategies, while good prognosis
patients may be treated with less burdensome interven-
tions, for example by less toxic chemotherapy regimens
[2,3]. Prognostic classifications use estimated survival to
identify poor prognosis patients eligible for alternative
treatments. However this approach only implicitly takes
the possible side effects of an alternative treatment into
account. Ideally both the expected gain in survival (bene-
fit) and the toxic side effects or burden due to treatment
(harm) are considered [4].
We apply a decision analytic approach proposed by
Glasziou and Irwig (1995) in which both benefit and
harm of an alternative treatment are explicitly specified
and weighed to determine which patients could profit
from this alternative treatment strategy [4].
The decision analytic approach is illustrated in Figure 1.
Benefit of treatment is the reduction in absolute risk of
cancer mortality due to treatment. Benefit increases line-
arly with risk of cancer mortality assuming that patients
with the highest risk have most to gain. Harm is the
increase in absolute risk of treatment mortality (e.g.
related to toxicity) due to treatment. The level of harm is
the same for all patients, assuming that for example the
toxicity of treatment is independent of prognosis. Patients
are candidates for more aggressive treatment when their
risk of cancer mortality is above the threshold, i.e. when
benefit is higher than harm [4].
As an example we consider high-dose chemotherapy (HD-
CT) as first line treatment to improve survival of patients
with nonseminomatous germ cell cancer. Several non-
randomised trials reported a higher survival for poor
prognosis patients treated with HD-CT as first line treat-
ment (including etoposide, ifosfamide, cisplatin) with
autologous stem cell support, compared to standard-dose
chemotherapy (SD-CT) (including bleomycin, etoposide,
cisplatin) [5-7]. Furthermore, HD-CT is currently consid-
ered in two RCTs by the European Organisation for
Research and Treatment of Cancer (EORTC) and by the
US intergroup [8,9]. However, HD-CT is related to a
higher toxicity, both during treatment (e.g. granulocyto-
penia, anaemia, nausea/vomiting, diarrhoea), shortly
after treatment (e.g. pulmonary toxicity) and long after
treatment (e.g. leukaemia, cardiovascular disease) [5,10].
So far studies on HD-CT focus on patients with a poor
prognosis according to the International Germ Cell Con-
sensus (IGCC) Classification [11]. The IGCC classification
combined 5 risk factors to define a good, intermediate
and poor prognosis group based on survival. Good prog-
nosis patients are considered eligible for less intensive
treatment reduce treatment related toxicity [12], interme-
diate prognosis patients usually receive standard treat-
ment, and poor prognosis patients are considered
candidates for more aggressive treatment. However, as
many other prognostic classifications, the IGCC classifica-
tion only considers survival in determining different prog-
nosis groups and does not take the possible (long-term)
harm of alternative treatments such as high-dose chemo-
therapy into account. By taking both expected harm and
benefit into account we can more precisely determine
which subgroup of patients might profit from high-dose
chemotherapy.
The aim of this study is to use a decision-analytic
approach to determine how high the risk of patients with
nonseminomatous germ cell cancer should be in order to
profit from high-dose chemotherapy with stem cell sup-
port. Estimates of benefit and harm of high-dose chemo-
therapy were based on currently available literature.
Methods
Of the different high-dose chemotherapy (HD-CT) treat-
ment strategies currently investigated we considered the
benefit and harm of the HD-CT approach by the German
testicular cancer group [5].
We considered benefit and harm till 10 years after treat-
ment, since longer-term evidence is scarce.
Benefit and harm of treatment, expressed on the same scale Figure 1
Benefit and harm of treatment, expressed on the same scale. 
Benefit of treatment (reduction in absolute risk) increases 
with risk, while harm of treatment (excess absolute risk, e.g. 
due to toxicity of treatment) is constant. Net benefit occurs 
only when risk is above the threshold. Adapted from 
Glasziou & Irwig (1995).
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Benefit
Benefit is based on the reduction in relative risk due to
HD-CT compared to standard chemotherapy.
Benefit is expressed as:
1 - (RC-MORT HD-CT/RC-MORT SD-CT)( 1 )
where RC-MORTHD-CT is the risk of cancer mortality with
HD-CT and RC-MORTSD-CT the risk of cancer mortality with
standard chemotherapy. This relative risk reduction trans-
lates into a decrease in absolute risk of cancer mortality at
the patient level. When HD-CT results in a relative risk
reduction of 25%, absolute risk decreases 10% for
patients with a risk of cancer mortality of 40% (0.25 × 40),
whereas for a patient with a risk of cancer mortality of
80% the absolute risk reduction is 20% (0.25 × 80).
Although benefit should preferably be based on results of
RCTs it will take several more years before the results of
RCTs comparing HD-CT to SD-CT become available. To
estimate risk of cancer mortality due to HD-CT and SD-CT
we therefore selected three observational studies; two
reporting on patients recently treated with SD-CT and one
study describing the long-term results of the HD-CT
approach by the German testicular cancer group
[5,13,14]. The selection of these studies was based on an
extensive search of the literature as in a previously pub-
lished meta-analysis [15].
These observational studies reported on either 5-year or
10-year survival. To estimate benefit we need the risk of
cancer mortality due to SD-CT and HC-CT 10 years after
treatment.
We therefore translated survival into risk of cancer mortal-
ity at 10 years.
Firstly, overall survival (SOVERALL) in each study was trans-
lated to risk of overall mortality due to treatment (ROVER-
ALL).
ROVERALL = 1 - SOVERALL (2)
From the overall risk of mortality we determine the risk of
cancer mortality (RC-MORT) by subtracting risk of treatment
mortality (RT-MORT). We ignore mortality due to other
causes since testicular cancer patients are relatively young.
RC-MORT = ROVERALL - RT-MORT (3)
Finally, we assumed that the relative increase in risk
between 5 years and 10 years after treatment was 20% and
increased the risk of cancer mortality accordingly [11].
The resulting estimates of cancer mortality 10 years after
treatment of the two studies on SD-CT were combined in
a weighted average by study size.
Harm
Harm is the excess risk of mortality due to HD-CT and is
assumed to remain comparatively constant. We consid-
ered the excess risk of mortality and morbidity using pub-
lished literature.
Treatment mortality consisted of early treatment mortality
(<6 months) and late treatment mortality (>6 months).
We based late treatment mortality (RLATE T-MORT) on the
incidence of long-term complications and fatality of these
long term complications once they occur. Fatality was
assumed to be identical for patients treated with HD-CT
or SD-CT once a complication occurred, although no
information was available on similarity of fatality
between patients treated with either SD-CT or HD-CT.
The excess risk of late treatment mortality is the difference
in incidence multiplied by the estimated fatality:
ΔRLATE T-MORT = (incidenceHD-CT - incidenceSD-CT) × fatality.
(4)
Late treatment morbidity (RLATE T-MORB) was made compa-
rable to mortality by weighing complications by their util-
ity value. Utility (U) is a measure of health related quality
of life, ranging from 0 to 1, where a weight of 1 corre-
sponds to perfect health and a weight of 0 corresponds to
a health state judged equivalent to death [16]. By express-
ing long-term complications in utilities, treatment related
morbidity could be directly compared with treatment
related mortality.
We estimated late treatment morbidity for SD-CT and
HD-CT by combining the incidence and utilities of long-
term complications up to 10 years after treatment. We
obtained utilities for long term complications from avail-
able literature [16].
The risk of excess late treatment morbidity for surviving
patients is:
ΔRLATE T-MORB = (incidenceHD-CT - incidenceSD-CT) × (1-U) × 
(1-fatality). (5)
Sensitivity analysis
We considered a conservative and an optimistic scenario
for benefit, since only observational data were available.
Further, a constant relative risk reduction assumes a linear
relationship between benefit and risk, where benefit is
absent for patients with no risk, and maximal for patients
with 100% risk of cancer mortality. Since treatment effect
is not necessarily similar for patients at varying risks weBMC Medical Informatics and Decision Making 2008, 8:1 http://www.biomedcentral.com/1472-6947/8/1
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also considered a non-linear relationship between benefit
and risk, in which benefit is absent for patients with no
risk or 100% risk and maximal for patients with a 50%
risk of cancer mortality. We determined the threshold for
such a parabolic relation between benefit and risk, for
both the optimistic and conservative scenario. Finally, we
calculated treatment thresholds for more aggressive ther-
apy when benefit and harm were varied over wide ranges.
All analyses were performed in Microsoft Excel 2000.
Results
Benefit
The three observational studies on which our estimate of
benefit of HD-CT was based are presented in Table 1. Son-
neveld et al. reported 10-year disease specific survival of
66% for 22 patients treated with SD-CT in their hospital
between 1987 and 1996 [17]. A RCT comparing standard
dose bleomycin-etoposide-cisplatin (BEP) with standard
dose etoposide-ifosfamide-cisplatin (VIP) reported a 5-
year overall survival of 60% for 181 poor prognosis
patients [13]. Schmoll et al. reported five-year survival of
73% for 182 patients treated with HD-CT between 1993
and 1999 [5].
Harm
Early treatment related mortality was 3% for patients
treated with SD-CT in RCT [18]. This is concordant with
an early treatment related mortality of 3% reported in
other series [19,20]. HD-CT early treatment related mor-
tality was 4%. The European Group for Blood and Marrow
Transplantation (EBMT) Solid Tumours registry has
recently reported an update of the mortality rate of germ
cell tumour patients treated in Europe between 1990 and
1999. The rate of toxic death, defined as any death occur-
ring within 100 days from grafting and not related to the
disease itself, declined from 8% in 1990 to 3% in 1999
(overall 5%) [20]. We estimate the excess early treatment
mortality as 1% (4-3%).
Table 2 lists the most common complications due to treat-
ment of non-seminomatous germ cell cancer [10,21]. For
each complication the incidence for SD-CT and HD-CT is
given and the suspected agent. Leukaemia is the main
cause of late treatment mortality in patients treated for
NSGCT. More patients are expected to develop leukaemia
after HD-CT than SD-CT (1.5 vs. 0.5%). With a mortality
of 70% for leukaemia, this results in a difference in late
treatment mortality of 0.7% [10,22,23]. Cardiovascular
disease further contributes to treatment mortality of
patients treated for NSGCT [10,24,25]. The incidence of
cardiovascular disease is estimated as 7% for SD-CT
patients. We estimated the incidence of cardiovascular
disease at, 10% for HD-CT patients, although no firm
empirical estimates were available for HD-CT. With a
fatality of 10% this results in 0.3% excess mortality. The
combination of early and late treatment related mortality
resulted in an estimated harm of 2%.
Other long-term complications vary from relatively mild
(Raynaud's phenomenon, ototoxicity) to severe (renal
failure) [5,10,26]. In estimating the difference in long-
term morbidity between SD-CT and HD-CT we only took
the more severe complications into account. No utility
was known for acute myeloid leukaemia. Although phys-
ical and emotional functioning of long term leukaemia
survivors is near normal, sexual functioning and fertility is
often affected [27]. We therefore estimated a utility of 0.9
for treatment related leukaemia.
The overall difference in utility weighted long-term mor-
bidity was 3.1%. The total harm due to HD-CT was
approximately 5% (excess mortality 2% + excess morbid-
ity 3.1%).
Treatment thresholds for HD-CT
To determine the benefift of high-dose over standard dose
chemotherapy 10 years after treatment we had to deter-
mine the risk of cancer mortality for both treatment strat-
egies.
Table 1: Survival and early treatment related death in non-seminomatous germ cell cancer patients treated with high-dose (HD) or 
standard-dose (SD) chemotherapy
Reference Treatment Year treatment N SOVERALL F-up ROV-MORT Early toxic death2 RC-MORT RC-MORT 10 yrs
Hinton et al. [13] SD 1987–1992 181 60% 5 40% 3% 37% 44%
Sonneveld et al. [17] SD 1987–1996 22 66%1 10 34% NA 31% 31%
Schmoll et al. [5] HD 1993–1999 182 73%1 5 27% 4% 23% 28%
SOVERALL = Overall survival at year of follow-up
F-up = follow-up in years
ROV-MORT = Risk of overall mortality at year of follow-up
RC-MORT = Risk of cancer mortality at year of follow-up
RC-MORT 10 yrs = Risk of cancer mortality 10 year after treatment
1 disease specific survival
2 early toxic death [5]: neutropenic infections (decreased white blood cells) and septic multi-organ failure. HD toxic death: any death occurring 
within 100 days from grafting and not directly related to the disease itself.BMC Medical Informatics and Decision Making 2008, 8:1 http://www.biomedcentral.com/1472-6947/8/1
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Firstly, we determined risk of overall mortality (see for-
mula 2) for the three observational studies, which were
40, 34 and 27% respectively (Table 2) [5,13,17]. By sub-
tracting treatment related mortality (formula 3), 4% for
high-dose chemotherapy and 3% for standard chemoter-
hapy, we obtained the risk of cancer mortality (37, 31 and
23% respectively). To obtain the risk of cancer mortality
10 years after treatment the estimates from Hinton et al.
and Schmoll et al. were increased with 20%.
Combined, the 203 patients treated with SD-CT had an
estimated 10-year risk of cancer mortality of 43%, which
was substantially higher than that for the 182 patients
treated with HD-CT chemotherapy (10-year risk of cancer
mortality 28%). The pooled estimate of benefit (see for-
mula 1) is 35% (RRR = 1 - (28%/43%)). For our conserv-
ative scenario we assume a benefit of 30% and for our
optimistic scenario a benefit of 40%.
At a benefit of 30% and only treatment related mortality
included in our estimate of harm (2%), patients with only
7% risk of cancer mortality or higher should be treated
with HD-CT (Figure 2). With a benefit of 40% the treat-
ment threshold was as low as 5%.
When we also take treatment related morbidity into
account in our estimate of harm (5%) and benefit is 30%,
patients with a 17% risk of cancer mortality or higher
should be treated with HD-CT (Figure 2). With a benefit
of 40% the treatment threshold was 12.5%.
Linear benefit (30%) and non-linear benefit (30%) vs. harm of  high dose chemotherapy, with harm defined as 10-year treat- ment related mortality (2%) or mortality plus morbidity (5%) Figure 2
Linear benefit (30%) and non-linear benefit (30%) vs. harm of 
high dose chemotherapy, with harm defined as 10-year treat-
ment related mortality (2%) or mortality plus morbidity (5%). 
The arrows indicate the thresholds to define poor prognosis 
(7% and 17% respectively for linear benefit, 4% and 11% 
respectively for non-linear benefit).
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Table 2: Incidence, mortality and utility of long term complications due to high-dose (HD) or standard-dose (SD) chemotherapy for 
non-seminomatous germ cell cancer.
Morbidity References Incidence Suspected agent Mortality Change in 
mortality3
Utility4 Change in 
morbidity5
SD HD
Therapy related leukaemia [10, 22, 23] 0.5% 1.5% Etoposide (< 2 g/m2, > 2 g/m2) 70% 0.7% 0.90 0.03%
Vascular toxicity [10, 16, 24, 25]
Raynaud's phenomenon 25% >25% Bleomycin - -
Cardiovascular disease 7% 10% Cisplatin 10% 0.3% 0.7 0.81%
Neurotoxicity [5, 10, 21]
Peripheral neuropathy 4% 5% Cisplatin - -
Ototoxicity 5% 65% Cisplatin 
(<400 mg/m2, > 400 mg/m2)
--
Nephrotoxicity [5, 10, 16]
Renal failure 1% 4% Cisplatin 0.6 1.2%
Hypertension 10% 24% Cisplatin 
(<400 mg/m2, > 400 mg/m2)
0.99 0.14%
Gonadal toxicity [10, 16, 26, 41]
Infertility1 50% >50% Cisplatin
Sexual functioning2 15% 27% 0.92 0.96%
Total 1% 3.14%
1 oligospermia/azoospermia
2 sexual dissatisfaction
3 Change in mortality calculated as (incidenceHD-CT - incidenceSD-CT) × fatality
4 Utility ranges from 0–1 and is a measure of health related quality of life
5 Change in morbidity calculated as (incidenceHD-CT - incidenceSD-CT) × (1-U) × (1-fatality).BMC Medical Informatics and Decision Making 2008, 8:1 http://www.biomedcentral.com/1472-6947/8/1
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When we assumed a non-linear benefit of 30% and a
harm of either 2 or 5% treatment thresholds were 4 and
11% respectively (Figure 2). With a non-linear benefit of
40% threshold values were below 10% (3% and 8%
respectively).
The estimates of benefit and harm determine the treat-
ment thresholds as shown in Figure 3 for treatment bene-
fits from 0 to 50% and harms from 0% to 40%. For non-
seminomatous germ cell cancer patients an estimated
benefit of 30% and harm of 5% resulted in a threshold of
17% (block 1). When we assumed a benefit of 40%, with
the same harm of 5%, the threshold decreased to 12.5%
(block 2). The same threshold could be obtained with a
smaller benefit, and a much smaller harm, for example
10% and 1% (block 3). We could also consider more
harmful therapies, which would naturally only be consid-
ered for types of cancer with a very poor prognosis. With
harm as high as 20% and a benefit of 50%, the treatment
threshold for such patients is a 40% risk of cancer mortal-
ity (block 4).
Discussion
We illustrated how decision analysis can explicitly assist
in defining poor prognosis testicular cancer patients who
have a net benefit of high-dose chemotherapy (HD-CT)
with stem cell support. Based on the currently available
literature we considered a conservative estimate of 30%
for the benefit and an optimistic estimate of 40%. We esti-
mated a harm of 5%, based on both treatment mortality
(2%) and treatment morbidity expressed in utilities (3%).
Even with a conservative estimate of 30% for the benefit
of treatment, and taking both treatment related mortality
and morbidity into account, patients with a risk of cancer
mortality of 17% or higher might already benefit from
HD-CT. With a benefit of 40% this threshold was reduced
to 12.5%. When we assumed benefit to be nonlinear,
treatment thresholds were 11 and 8% for benefit of 30
and 40% respectively. Although this decision analysis was
specific for the defining high-risk patients with germ cell
tumors, it is in line with the more general approach for the
selection of patients for clinical trials described by Vickers
et al.[28].
To what extent is the group of patients above the thresh-
old comparable to the poor prognosis patients as defined
by the IGCC classification?
The IGCC classification does not explicitly use risk thresh-
olds to determine prognosis groups.
However, we can use previously developed multivariable
models to study the risk distribution within the 3 IGCC
classification groups [29,30].
This also allows us to determine how many patients in
each prognosis group have a risk above the treshold of
17% and how many patients have a risk below the tresh-
old, i.e. for which patients does the use of the treatment
treshold based on our decision analysis result in a change
in treatment.
The mean 10-year predicted risks of mortality of the good,
intermediate and poor prognosis groups were 7, 19 and
46% respectively (Figure 4). We can define a threshold for
the good prognosis patients such that the number of
patients is identical to the number with the IGCC classifi-
cation, and similarly for the poor prognosis group. The
risk thresholds were 11% and 28% between the good and
intermediate prognosis group, and between the interme-
diate and the poor prognosis group respectively.
According to the threshold, 881 of 3048 patients (29%)
should be treated with HD-CT. Compared to the IGCC
classification 28 good prognosis patients (1%) and 409
intermediate prognosis patients (13%), who would get
SD-CT according to the IGCC classification, have a risk
above the 17% threshold and therefore should get HD-
CT. Fifty-one poor prognosis patients, who would get HD-
CT according to the IGCC classification, have a risk below
the threshold and should therefore get SD-CT.
The IGCC classification and our decision analysis hence
largely disagree on intermediate prognosis patients as can-
didates for HD-CT. In the future, a more refined prognos-
Thresholds according to risk with standard treatment for a  range of hypothetical benefits (reduction in relative risk, RR)  and harms associated with a more aggressive treatment Figure 3
Thresholds according to risk with standard treatment for a 
range of hypothetical benefits (reduction in relative risk, RR) 
and harms associated with a more aggressive treatment. 1. 
benefit 30%, harm = 5%, threshold = 17% (- - -), 2. benefit 
40%, harm = 5%, threshold = 12.5% (--), 3. benefit 10%, harm 
= 1%, threshold = 12.5% (--), 4. benefit 50%, harm = 20%, 
threshold = 40% (----).
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tic classification is desirable, with prognostic groups
defined in more detail and with more powerful predic-
tors, e.g. new biomarkers [31,32].
Although we considered a conservative and optimistic
estimate of the benefit of HD-CT our estimate may still be
too optimistic. Differences in treatment other than HD-
CT may have affected the difference in survival between
patients treated with SD-CT and patients treated with HD-
CT. Firstly the patients treated with SD-CT were mainly
treated in the US whereas patients treated with HD-CT
were treated in Germany. However, the estimated risk of
cancer mortality for SD-CT is in line with the IGCC sur-
vival estimate for poor prognosis patients adjusted for
year of treatment, which is based on patients treated in
both Europe and the US [15]. Secondly, patients treated
with SD-CT were treated earlier than patients treated with
HD-CT. Improvements over time in second line treatment
may have effected the difference in survival [18].
Our estimate of harm may be too low. We estimated harm
due to treatment related mortality and morbidity at 10
years after treatment. Direct estimates of early treatment
mortality were available for both SD-CT and HD-CT.
However information on long term complications is
merely available for SD-CT, and limited for HD-CT. As a
consequence our estimate of etoposide induced leukae-
mia, which is very difficult to cure, may be too low.
Similarly, the harm due to complications such as cardio-
vascular disease and hypertension may be higher since
they pose a lifetime risk. Finally, little is known about the
harm due to chronic fatigue and neuropsychological
sequelae [18]. Figure 3 helps to directly calculate the risk
threshold if more conservative assumptions are made. For
example, when the relative risk reduction due to HD-CT is
only 20% and the harm 8%, only patients with at least a
40% risk will benefit from more aggressive treatment.
Our analysis has some other limitations. To compare
harm and benefit of HD-CT we expressed both in 10-year
risks, without considering the time of the event since treat-
ment (early or late). This is a simplification. An alternative
would be a more extensive decision analysis, in which
expected life years and the probability of complications
are modelled, e.g. with a Markov model with yearly cycles
[33]. However given the uncertainty in the estimates of
harm and benefit such a more complicated model was not
considered desirable.
We also did not consider costs of HD-CT or SD-CT. There
are currently no data available on the difference in costs
between HD-CT and SD-CT for testicular cancer patients
but in other diseases, such as non-Hodgkin's lymphoma,
multiple myeloma and breast cancer, the costs of HD
chemotherapy have been reported to be one to four times
higher than SD [34]. Hence, HD-CT needs to have a sub-
stantial net benefit to be relevant from a societal perspec-
tive.
Evidence of the benefit of HD-CT as first line treatment in
the literature has not been conclusive, and the results of
two ongoing RCTs have to be awaited for more reliable
decision making. One RCT by the EORTC (BEP vs. high-
dose VIP) is still including poor prognosis patients [8].
The inclusion of intermediate and poor prognosis patients
for an RCT by the US intergroup (BEP vs. high-dose CEC)
has closed and preliminary results have been presented
[9,35]. There was no significant difference in complete
response after 1 year between standard and high-dose
chemotherapy (48 vs. 52%). We will have to await the
publication of the final results of these RCTs before a
more precise estimate of the benefit of HD-CT can be
made.
Based on the number of patients enrolled in these trials, a
relative risk reduction over approximately 50% can be
detected with sufficient statistical power. This may be an
optimistic estimate, and results of the trials may be incon-
clusive when HD-CT in fact has a smaller effect. Our anal-
ysis suggests that HD-CT may not be beneficial for the full
group of intermediate prognosis patients, especially
because of excess long-term mortality and morbidity. Spe-
cial attention should be given to the intermediate progno-
Distribution of predicted 10-year risk of mortality for the  good, intermediate and poor prognosis groups of the IGCC  classification Figure 4
Distribution of predicted 10-year risk of mortality for the 
good, intermediate and poor prognosis groups of the IGCC 
classification. Mean risk of good, intermediate and poor prog-
nosis were 7, 19 and 46% respectively.
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sis patients in the analysis of the RCT that includes these
patients [9]. Further, it is important that more precise
information becomes available on the long term compli-
cations of HD-CT by longer follow-up, since testicular
cancer occurs mostly at a young age.
Besides HD-CT other approaches are being investigated to
improve survival of NSGCT patients, such as dose intensi-
fication and the introduction of new agents [36-38].
A recently published phase II trial investigating the inten-
sive induction chemotherapy carboplatin, bleomycin,
vincristine, cisplatin + bleomycin, etoposide, cisplatin (C-
BOP/BEP) showed promising results with 2-year survival
of 94 and 85% for intermediate and poor prognosis
patients respectively. However, 2-year progression free
survival was much lower for poor prognosis patients
(56%) suggesting that the benefit will be smaller at 5 or
10-year follow-up [39].
Furthermore the EORTC currently conducts a RCT tar-
geted especially at intermediate prognosis patients which
investigates the combination of paclitaxel with BEP (T-
BEP) [40].
The results of these trials can be incorporated in the deci-
sion analytic approach described in this study to deter-
mine which treatment is optimal at what harm and
benefit.
Conclusion
In conclusion, we illustrated how decision analysis can
support treatment choices on more aggressive therapy.
From the decision analysis we learn at what risk a treat-
ment becomes beneficial. A prognostic model or prognos-
tic classification can then be used to estimate the risk of an
individual patient or a subgroup of patients. This
approach can be adapted to new results from ongoing tri-
als and extended to many other cancers to explicitly define
candidates for more aggressive treatments. Hence,
patients who are expected to benefit will be treated more
aggressively, without overtreatment of those at relatively
low risk, and patients who are not expected to benefit will
be treated in a more standard way, without undertreat-
ment of those at relatively high risk.
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